Xueqi Ou

1.6k total citations · 3 hit papers
22 papers, 1.2k citations indexed

About

Xueqi Ou is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xueqi Ou has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Cancer Research and 8 papers in Oncology. Recurrent topics in Xueqi Ou's work include Cancer-related molecular mechanisms research (7 papers), MicroRNA in disease regulation (6 papers) and Circular RNAs in diseases (5 papers). Xueqi Ou is often cited by papers focused on Cancer-related molecular mechanisms research (7 papers), MicroRNA in disease regulation (6 papers) and Circular RNAs in diseases (5 papers). Xueqi Ou collaborates with scholars based in China, United States and Hong Kong. Xueqi Ou's co-authors include Hailin Tang, Yutian Zou, Guanfeng Gao, Xiangsheng Xiao, Xiaoming Xie, Shaoquan Zheng, Song Wu, Jindong Xie, Yuhui Tang and Lijuan Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and Molecular Cancer.

In The Last Decade

Xueqi Ou

20 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer

2022 191 citations Yutian Zou, Feng Ye et al. Advanced Science profile →
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer

2024 106 citations Xueqi Ou, Yeru Tan et al. Drug Resistance Updates profile →
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

2024 50 citations Jindong Xie, Xinpei Deng et al. SHILAP Revista de lepidopterología profile →

Peers

Xueqi Ou

ONCOL

PRM

IMMUN

Yingke Liang China

Chengli Du China

Jianguo Sun China

Ziyou Lin China

Hailong Wang China

Yushuai Mi China

Sida Qin China

Marco Giallombardo Belgium

Lu Zang China

Jieyi Ma China

Yingke Liang China

Xueqi Ou

763 ×0.9

551 ×0.9

253 ×0.9

ONCOL

158 ×0.8

PRM

124 ×1.0

IMMUN

Citations per year, relative to Xueqi Ou Xueqi Ou (= 1×) peers Yingke Liang

Countries citing papers authored by Xueqi Ou

Since Specialization

Citations

This map shows the geographic impact of Xueqi Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xueqi Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xueqi Ou more than expected).

Fields of papers citing papers by Xueqi Ou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xueqi Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xueqi Ou. The network helps show where Xueqi Ou may publish in the future.

Co-authorship network of co-authors of Xueqi Ou

This figure shows the co-authorship network connecting the top 25 collaborators of Xueqi Ou. A scholar is included among the top collaborators of Xueqi Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xueqi Ou. Xueqi Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zeng, Xiaojuan, Minghui Liu, Yi Si, et al.. (2025). [Expert consensus: reducing free-sugar for caries prevention].. PubMed. 60(4). 311–319.

Xie, Jindong, Wenjian Liu, Xinpei Deng, et al.. (2025). Paracrine Orchestration of Tumor Microenvironment Remodeling Induced by GLO1 Potentiates Lymph Node Metastasis in Breast Cancer. Advanced Science. 12(32). e00722–e00722. 6 indexed citations

Xie, Jiaheng, Pengpeng Zhang, Dan Wu, et al.. (2025). USP5-Mediated PD-L1 deubiquitination regulates immunotherapy efficacy in melanoma. Journal of Translational Medicine. 23(1). 778–778.

Xie, Jindong, Anli Yang, Qianwen Liu, et al.. (2024). Single‐cell RNA sequencing elucidated the landscape of breast cancer brain metastases and identified ILF2 as a potential therapeutic target. Cell Proliferation. 57(11). e13697–e13697. 28 indexed citations

Xie, Jindong, Xinpei Deng, Yuhui Tang, et al.. (2024). Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies. SHILAP Revista de lepidopterología. 3(1). e156–e156. 50 indexed citations breakdown →

Ou, Xueqi, Yeru Tan, Jindong Xie, et al.. (2024). Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer. Drug Resistance Updates. 73. 101063–101063. 106 indexed citations breakdown →

Ou, Xueqi, Yeru Tan, Guanfeng Gao, et al.. (2023). Development and Verification of a Prognostic Stemness-Related Gene Signature in Triple-Negative Breast Cancer. Journal of Oncology. 2023. 1–13. 1 indexed citations

Zeng, Yan, Wei Du, Song Wu, et al.. (2023). Hsa_circ_0060467 promotes breast cancer liver metastasis by complexing with eIF4A3 and sponging miR-1205. Cell Death Discovery. 9(1). 153–153. 46 indexed citations

Wang, Zehao, Lu Yang, Peng Wu, et al.. (2022). The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Molecular Cancer. 21(1). 29–29. 118 indexed citations

10.

Zou, Yutian, Feng Ye, Yanan Kong, et al.. (2022). The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Advanced Science. 10(5). e2203699–e2203699. 191 indexed citations breakdown →

11.

Xie, Jindong, Yutian Zou, Feng Ye, et al.. (2022). A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer. Frontiers in Cell and Developmental Biology. 9. 795600–795600. 28 indexed citations

12.

Liu, Peng, Zehao Wang, Xueqi Ou, et al.. (2022). The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition. Molecular Cancer. 21(1). 198–198. 140 indexed citations

13.

Xie, Jindong, Shaoquan Zheng, Yutian Zou, et al.. (2022). Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC. Frontiers in Immunology. 13. 1022147–1022147. 37 indexed citations

14.

Zhang, Kaiming, et al.. (2021). A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery. Journal of Personalized Medicine. 11(5). 413–413. 4 indexed citations

15.

Zhang, Kaiming, et al.. (2021). A Novel Pyroptosis-Associated Long Non-coding RNA Signature Predicts Prognosis and Tumor Immune Microenvironment of Patients With Breast Cancer. Frontiers in Cell and Developmental Biology. 9. 727183–727183. 34 indexed citations

16.

Kong, Yanan, Xueqi Ou, Xing Li, et al.. (2020). LGR6 Promotes Tumor Proliferation and Metastasis through Wnt/β-Catenin Signaling in Triple-Negative Breast Cancer. Molecular Therapy — Oncolytics. 18. 351–359. 18 indexed citations

17.

Zhang, Xiaoyan, et al.. (2020). Diallyl disulfide regulates energy metabolism by targeting AMP-activated protein kinase alpha1 in human gastric cancer cells. 32(3). 1 indexed citations

18.

Liu, Feng, et al.. (2019). MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer. Journal of Cancer Research and Therapeutics. 15(7). 1597–1597. 37 indexed citations

19.

Tang, Hailin, Cailu Song, Feng Ye, et al.. (2019). miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. Journal of Cellular and Molecular Medicine. 23(12). 8114–8127. 32 indexed citations

20.

Ye, Feng, Guanfeng Gao, Yutian Zou, et al.. (2019). circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer. Molecular Therapy — Nucleic Acids. 18. 88–98. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact